127 related articles for article (PubMed ID: 36156366)
21. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.
Lovejoy DB; Richardson DR
Curr Med Chem; 2003 Jun; 10(12):1035-49. PubMed ID: 12678675
[TBL] [Abstract][Full Text] [Related]
22. Novel thiosemicarbazones regulate the signal transducer and activator of transcription 3 (STAT3) pathway: inhibition of constitutive and interleukin 6-induced activation by iron depletion.
Lui GY; Kovacevic Z; V Menezes S; Kalinowski DS; Merlot AM; Sahni S; Richardson DR
Mol Pharmacol; 2015; 87(3):543-60. PubMed ID: 25561562
[TBL] [Abstract][Full Text] [Related]
23. Trypanotoxic activity of thiosemicarbazone iron chelators.
Ellis S; Sexton DW; Steverding D
Exp Parasitol; 2015 Mar; 150():7-12. PubMed ID: 25595343
[TBL] [Abstract][Full Text] [Related]
24. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.
Yuan J; Lovejoy DB; Richardson DR
Blood; 2004 Sep; 104(5):1450-8. PubMed ID: 15150082
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells.
Noulsri E; Richardson DR; Lerdwana S; Fucharoen S; Yamagishi T; Kalinowski DS; Pattanapanyasat K
Am J Hematol; 2009 Mar; 84(3):170-6. PubMed ID: 19140186
[TBL] [Abstract][Full Text] [Related]
26. The Anticancer Agent, Di-2-Pyridylketone 4,4-Dimethyl-3-Thiosemicarbazone (Dp44mT), Up-Regulates the AMPK-Dependent Energy Homeostasis Pathway in Cancer Cells.
Krishan S; Richardson DR; Sahni S
Biochim Biophys Acta; 2016 Dec; 1863(12):2916-2933. PubMed ID: 27639899
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional regulation of the cyclin-dependent kinase inhibitor, p21
Moussa RS; Kovacevic Z; Bae DH; Lane DJR; Richardson DR
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):761-774. PubMed ID: 29032246
[TBL] [Abstract][Full Text] [Related]
28. Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types.
Moussa RS; Kovacevic Z; Richardson DR
Oncotarget; 2015 Oct; 6(30):29694-711. PubMed ID: 26335183
[TBL] [Abstract][Full Text] [Related]
29. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.
Chaston TB; Lovejoy DB; Watts RN; Richardson DR
Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494
[TBL] [Abstract][Full Text] [Related]
30. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation.
Le NT; Richardson DR
Blood; 2004 Nov; 104(9):2967-75. PubMed ID: 15251988
[TBL] [Abstract][Full Text] [Related]
31. Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking.
Xu X; Sutak R; Richardson DR
Mol Pharmacol; 2008 Mar; 73(3):833-44. PubMed ID: 18029550
[TBL] [Abstract][Full Text] [Related]
32. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIalpha in breast cancer cells.
Rao VA; Klein SR; Agama KK; Toyoda E; Adachi N; Pommier Y; Shacter EB
Cancer Res; 2009 Feb; 69(3):948-57. PubMed ID: 19176392
[TBL] [Abstract][Full Text] [Related]
33. Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential as a molecular target for cancer therapy.
Fang BA; Kovačević Ž; Park KC; Kalinowski DS; Jansson PJ; Lane DJ; Sahni S; Richardson DR
Biochim Biophys Acta; 2014 Jan; 1845(1):1-19. PubMed ID: 24269900
[TBL] [Abstract][Full Text] [Related]
34. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
[TBL] [Abstract][Full Text] [Related]
35. Local delivery of iron chelators reduces in vivo remodeling of a calcium phosphate bone graft substitute.
Drager J; Sheikh Z; Zhang YL; Harvey EJ; Barralet JE
Acta Biomater; 2016 Sep; 42():411-419. PubMed ID: 27449336
[TBL] [Abstract][Full Text] [Related]
36. Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: identification of novel thiosemicarbazones and therapeutics that prevent this effect.
Quach P; Gutierrez E; Basha MT; Kalinowski DS; Sharpe PC; Lovejoy DB; Bernhardt PV; Jansson PJ; Richardson DR
Mol Pharmacol; 2012 Jul; 82(1):105-14. PubMed ID: 22508546
[TBL] [Abstract][Full Text] [Related]
37. Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.
Yu Y; Suryo Rahmanto Y; Richardson DR
Br J Pharmacol; 2012 Jan; 165(1):148-66. PubMed ID: 21658021
[TBL] [Abstract][Full Text] [Related]
38. The role of NDRG1 in the pathology and potential treatment of human cancers.
Bae DH; Jansson PJ; Huang ML; Kovacevic Z; Kalinowski D; Lee CS; Sahni S; Richardson DR
J Clin Pathol; 2013 Nov; 66(11):911-7. PubMed ID: 23750037
[TBL] [Abstract][Full Text] [Related]
39. New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer.
Kontoghiorghes GJ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430469
[TBL] [Abstract][Full Text] [Related]
40. NDRG1 suppresses basal and hypoxia-induced autophagy at both the initiation and degradation stages and sensitizes pancreatic cancer cells to lysosomal membrane permeabilization.
Sahni S; Gillson J; Park KC; Chiang S; Leck LYW; Jansson PJ; Richardson DR
Biochim Biophys Acta Gen Subj; 2020 Aug; 1864(8):129625. PubMed ID: 32335136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
